<DOC>
	<DOCNO>NCT01670084</DOCNO>
	<brief_summary>In study researcher want find side effect new drug Philadelphia chromosome-positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) chronic myelogenous leukemia ( CML ) blastic phase ( BP ) disease respond well nilotinib combined standard hyper-CVAD therapy rather hyper-CVAD alone . Hyper-CVAD combination cyclophosphamide , mesna , vincristine ( vincristine sulfate ) , doxorubicin ( doxorubicin hydrochloride ) , dexamethasone , methotrexate , cytarabine , rituximab ( patient cluster differentiation [ CD ] 20 positive disease ) . Researchers n't know way drug may affect people</brief_summary>
	<brief_title>Nilotinib Combination Chemotherapy Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Blastic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine clinical efficacy ( 2-year disease-free survival rate ) nilotinib combination chemotherapy adult patient newly diagnose Philadelphia chromosome positive B-cell acute lymphoblastic leukemia blast crisis chronic myeloid leukemia . SECONDARY OBJECTIVES : I . Determine 2-year overall survival rate . II . Determine complete response ( CR ) rate ( hematological , cytogenetic , molecular ) patient treat regimen . III . Determine CR duration patient treat regimen . IV . Assess safety toxicity regimen National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . TERTIARY OBJECTIVES : I. Assess prognostic predictive factor patient treat regimen . II . Assess cerebrospinal fluid ( CSF ) penetration Nilotinib ( CSF Nilotinib level ) human . III . Assess Abelson ( ABL ) kinase domain mutation frequency diagnosis , therapy , relapse . OUTLINE : INDUCTION AND CONSOLIDATION SCHEDULE A ( COURSES 1 , 3 , 5 , 7 ) : Patients receive cyclophosphamide intravenously ( IV ) twice daily ( BID ) 2 hour day 1-3 , mesna IV continuously day 1-3 , doxorubicin hydrochloride IV push day 4 , vincristine sulfate IV day 4 11 , dexamethasone IV orally ( PO ) day 1-4 11-14 , methotrexate intrathecally ( IT ) day 2 , cytarabine IT day 8 , nilotinib PO BID day 1-14 . Patients CD20-positive disease also receive rituximab IV day 1 11 . INDUCTION AND CONSOLIDATION SCHEDULE B ( COURSES 2 , 4 , 6 , 8 ) : Patients receive methotrexate IV continuously 24 hour day 1 , cytarabine IV 2 hour day 2-3 , leucovorin calcium IV every 6 hour day 2-3 , methotrexate IT day 2 , cytarabine IT day 8 , nilotinib PO BID day 1-14 . Patients CD20-positive disease also receive rituximab IV day 1 11 . MAINTENANCE ( COURSES 9-32 ) : Patients receive nilotinib PO BID day 1-28 ( day 1-14 minimal residual disease [ MRD ] -positive patient ) , vincristine sulfate IV day 1 , prednisone PO day 1 5 . Patients also receive rituximab IV day 1 course CD20-positive , every sixth course MRD-negative , every third course MRD-positive . INTENSIFICATION : Patients receive treatment Schedule A course 14 21 maintenance therapy treatment Schedule B course 15 22 maintenance therapy . DELAYED MAINTENANCE ( COURSES 33-36 ) : Patients receive nilotinib PO BID day 1 84 . Treatment repeat every 84 day 4 course . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6-12 month 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Untreated , histological confirm Philadelphia positive Bcell acute lymphoblastic leukemia chronic myeloid leukemia blastphase lymphoid lineage ( bilineal , biphenotypic undifferentiated ) per World Health Organization ( WHO ) criteria ; NOTE : Dexamethasone ( corticosteroid ) use allow needed start chemotherapy ; prior imatinib dasatinib therapy CML chronic phase ( CP ) accelerate phase ( AP ) allow Molecular cytogenetic documentation BCRABL fusion gene via follow : reverse transcriptasepolymerase chain reaction ( RTPCR ) , Gbanding , fluorescence situ hybridization ( FISH ) test peripheral blood and/or bone marrow sample Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Magnesium/potassium/phosphorus within normal limit ( WNL ) Serum amylase = &lt; 1.5 x upper limit normal ( ULN ) Lipase = &lt; 1.5 x ULN Total bilirubin &lt; 1.5 x ULN ( apply patient isolate hyperbilirubinemia [ e.g. , Gilbert 's disease ] , situation direct bilirubin = &lt; 2 x ULN ) Alkaline phosphatase = &lt; 3 x ULN Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) = &lt; 3 x ULN Serum glutamic pyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 3 x ULN Creatinine = &lt; 1.5 x ULN Negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Provide inform write consent Willing return Mayo Clinic Rochester Mayo Clinic Arizona followup active monitoring phase study Willing provide CSF blood sample correlative research purpose Any follow study involve investigational agent ( ) whose genotoxic , mutagenic teratogenic effect develop fetus newborn unknown : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception throughout study 3 month completion study treatment Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive ( even highly active antiretroviral therapy [ HAART ] ) Uncontrolled intercurrent illness include , limited , ongoing active infection , psychiatric illness/social situation would limit compliance study requirement Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 3 year prior registration ; EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix History myocardial infarction = &lt; 12 month , congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Previous treatment chemotherapy tyrosine kinase inhibitor ( prior imatinib dasatinib CMLCP/AP allow ) Impaired cardiac function include one following : Inability monitor QT interval electrocardiogram ( ECG ) Congenital long QT syndrome know family history long QT syndrome Cardiac ejection fraction ( EF ) &lt; 45 % Clinically significant rest brachycardia ( &lt; 50 beat per minute ) Corrected QT interval ( QTc ) &gt; 450 msec baseline ECG ; QTc &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) History presence clinically significant ventricular atrial tachyarrhythmias Patients receive medication substance strong moderate inhibitor cytochrome P450 3A4 ( CYP3A4 ) ; use follow strong moderate inhibitor prohibit = &lt; 7 day prior registration : Strong Inhibitors CYP3A4 ; &gt; 5fold increase plasma area curve ( AUC ) value 80 % decrease clearance Indinavir ( Crixivan® ) Nelfinavir ( Viracept® ) Atazanavir ( Reyataz® ) Ritonavir ( Norvir® ) Clarithromycin ( Biaxin® , Biaxin XL® ) Itraconazole ( Sporanox® ) Ketoconazole ( Nizoral® ) Nefazodone ( Serzone® ) Saquinavir ( Fortovase® , Invirase® ) Telithromycin ( Ketek® ) Moderate Inhibitors CYP3A4 ; &gt; 2fold increase plasma AUC value 5080 % decrease clearance Aprepitant ( Emend® ) Erythromycin ( Erythrocin® , E.E.S . ® , EryTab® , Eryc® , EryPed® , PCE® ) Fluconazole ( Diflucan® ) Grapefruit juice Verapamil ( Calan® , Calan SR® , CoveraHS® , Isoptin SR® , Verelan® , Verelan PM® ) Diltiazem ( Cardizem® , Cardizem CD® , Cardizem LA® , Cardizem SR® , Cartia XT™ , Dilacor XR® , Diltia XT® , Taztia XT™ , Tiazac® ) Patients receive medication substance inducer CYP3A4 ; use follow inducer prohibit = &lt; 7 day prior registration * Inducers CYP3A4 Efavirenz ( Sustiva® ) Nevirapine ( Viramune® ) Carbamazepine ( Carbatrol® , Epitol® , Equetro™ , Tegretol® , TegretolXR® ) Modafinil ( Provigil® ) Phenobarbital ( Luminal® ) Phenytoin ( Dilantin® , Phenytek® ) Pioglitazone ( Actos® ) Rifabutin ( Mycobutin® ) Rifampin ( Rifadin® ) St. John 's wort Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection gastric bypass surgery ) Acute chronic pancreatic disease Known cytopathologically confirm central nervous system ( CNS ) infiltration Acute chronic liver disease severe renal disease consider unrelated cancer History significant congenital acquire bleed disorder unrelated cancer Major surgery = &lt; 4 week prior registration recover prior surgery Treatment investigational agent = &lt; 14 day registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>